Form 4: Gain Therapeutics Director, Jeffrey Scott Riley, Acquires 30,000 Shares of Common Stock

Director Jeffrey Scott Riley purchased 30,000 shares of Gain Therapeutics, Inc. common stock at an average price of $3.859 on March 28, 2024.

Summary

• On March 28, 2024, Jeffrey Scott Riley, a director of Gain Therapeutics, Inc., acquired 30,000 shares of common stock.
• The shares were purchased at a weighted average price of $3.859 per share.
• The price range for the multiple transactions was between $3.7098 and $3.924.
• Following the transaction, Mr. Riley directly owns 30,000 shares of Gain Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the purchase is relatively small and may not be highly significant.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's value and future prospects.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates